IL163525A0 - A follistatin domain containing protein - Google Patents

A follistatin domain containing protein

Info

Publication number
IL163525A0
IL163525A0 IL16352503A IL16352503A IL163525A0 IL 163525 A0 IL163525 A0 IL 163525A0 IL 16352503 A IL16352503 A IL 16352503A IL 16352503 A IL16352503 A IL 16352503A IL 163525 A0 IL163525 A0 IL 163525A0
Authority
IL
Israel
Prior art keywords
containing protein
domain containing
follistatin domain
follistatin
protein
Prior art date
Application number
IL16352503A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL163525A0 publication Critical patent/IL163525A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
IL16352503A 2002-02-21 2003-02-21 A follistatin domain containing protein IL163525A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35784502P 2002-02-21 2002-02-21
US43464402P 2002-12-20 2002-12-20
PCT/US2003/005151 WO2003072715A2 (fr) 2002-02-21 2003-02-21 Proteine contenant un domaine de follistatine

Publications (1)

Publication Number Publication Date
IL163525A0 true IL163525A0 (en) 2005-12-18

Family

ID=27767536

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16352503A IL163525A0 (en) 2002-02-21 2003-02-21 A follistatin domain containing protein

Country Status (12)

Country Link
US (4) US7192717B2 (fr)
EP (1) EP1572909A4 (fr)
JP (2) JP4429729B2 (fr)
KR (1) KR20040094709A (fr)
AU (1) AU2003217612A1 (fr)
BR (1) BR0307907A2 (fr)
CA (1) CA2476887A1 (fr)
IL (1) IL163525A0 (fr)
MX (1) MXPA04008150A (fr)
NO (1) NO20043886L (fr)
PL (1) PL375045A1 (fr)
WO (1) WO2003072715A2 (fr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL374966A1 (en) * 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
KR20040094709A (ko) 2002-02-21 2004-11-10 와이어쓰 폴리스타틴 도메인을 포함하는 단백질
AU2003267246A1 (en) * 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CN1829532A (zh) * 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
WO2005041748A2 (fr) 2003-09-12 2005-05-12 Minnow Medical, Llc Remodelage excentrique et/ou ablation d'une matiere atherosclereuse
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2574777C (fr) * 2004-07-23 2015-09-01 Acceleron Pharma Inc. Polypeptides du recepteur actrii, procedes et compositions correspondants
CA2575563A1 (fr) * 2004-08-12 2006-02-23 Wyeth Traitement combine du diabete, de l'obesite et de maladies cardiovasculaires, faisant appel a des inhibiteurs de gdf-8
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
CN101137906A (zh) * 2005-03-23 2008-03-05 惠氏公司 对gdf-8调节剂的免疫应答的检测
MX2007011400A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
CN101379086B (zh) 2005-08-19 2013-07-17 惠氏公司 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1973559B1 (fr) 2005-11-23 2013-01-09 Acceleron Pharma Inc. Antagonistes de l'activine-actriia et utilisations pour activer la croissance osseuse
CN101410132A (zh) * 2006-03-28 2009-04-15 惠氏公司 用于治疗骨疾病的gdf-9/bmp-15调节剂
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
JP5479901B2 (ja) 2006-10-18 2014-04-23 べシックス・バスキュラー・インコーポレイテッド 身体組織に対する所望の温度作用の誘発
AU2007310991B2 (en) 2006-10-18 2013-06-20 Boston Scientific Scimed, Inc. System for inducing desirable temperature effects on body tissue
ES2546773T3 (es) 2006-10-18 2015-09-28 Vessix Vascular, Inc. Energía de RF sintonizada y caracterización eléctrica de tejido para el tratamiento selectivo de tejidos diana
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
RS52537B (en) * 2006-12-18 2013-04-30 Acceleron Pharma Inc. ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT
TWI480048B (zh) * 2007-02-01 2015-04-11 Acceleron Pharma Inc 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201808334A (zh) * 2007-02-09 2018-03-16 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
WO2008109779A2 (fr) * 2007-03-07 2008-09-12 The Johns Hopkins University Utilisation d'un gène associé à la follistatine-like (flrg) pour accroître la masse musculaire
EP2207562B1 (fr) * 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Antagonistes de l'activine-actriia et utilisations pour réduire ou empêcher la sécrétion de fsh
WO2009054967A2 (fr) * 2007-10-22 2009-04-30 Synthes (U.S.A.) Compositions pour l'administration d'antibiotiques glycopeptidiques
US8637455B2 (en) * 2007-10-22 2014-01-28 Affinergy, Llc Compositions and methods for delivery of glycopeptide antibiotics to medical device surfaces
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CA2729100C (fr) 2008-06-26 2018-01-02 Acceleron Pharma Inc. Procedes pour administrer un antagoniste d'activine-actriia et surveiller des patients traites
TW201803586A (zh) * 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2009314133B2 (en) 2008-11-17 2015-12-10 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
US8138142B2 (en) * 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EP3345921A1 (fr) 2009-06-08 2018-07-11 Acceleron Pharma Inc. Utilisation d'anticorps anti-actriib pour l'augmentation d'adipocytes thermogènes
ES2836534T3 (es) 2009-06-12 2021-06-25 Acceleron Pharma Inc Proteínas de fusión de ActRIIB-Fc truncadas
JP6211767B2 (ja) * 2009-09-09 2017-10-11 アクセルロン ファーマ， インコーポレイテッド ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
CA2779472C (fr) * 2009-11-03 2021-03-16 Acceleron Pharma Inc. L'utilisation d'une composition renfermant un polypeptide recepteur d'activine de type iib pour le traitement de steatose hepatique
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CN103068330B (zh) 2010-04-09 2016-06-29 Vessix血管股份有限公司 用于治疗组织的功率发生和控制装置
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8895011B2 (en) * 2010-05-27 2014-11-25 The University Of Tokyo Insulin-resistance-improving drug
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
WO2012023085A1 (fr) 2010-08-20 2012-02-23 Wyeth Llc Culture cellulaire de cellules adaptées exemptes de facteur de croissance
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
CA2817008A1 (fr) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Agents de liaison a actriia et leurs utilisations
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
WO2013013156A2 (fr) 2011-07-20 2013-01-24 Boston Scientific Scimed, Inc. Dispositifs et procédés percutanés de visualisation, de ciblage et d'ablation de nerfs
AU2012287189B2 (en) 2011-07-22 2016-10-06 Boston Scientific Scimed, Inc. Nerve modulation system with a nerve modulation element positionable in a helical guide
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
WO2013059202A1 (fr) 2011-10-18 2013-04-25 Boston Scientific Scimed, Inc. Cathéter à ballonnet à traversée intégrée
KR20140077977A (ko) 2011-10-21 2014-06-24 화이자 인코포레이티드 철을 첨가하여 세포 배양을 개선하는 방법
CN104023662B (zh) 2011-11-08 2018-02-09 波士顿科学西美德公司 孔部肾神经消融
WO2013074813A1 (fr) 2011-11-15 2013-05-23 Boston Scientific Scimed, Inc. Dispositif et procédés pour surveiller la modulation nerveuse rénale
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
WO2013096913A2 (fr) 2011-12-23 2013-06-27 Vessix Vascular, Inc. Procédés et appareils pour remodéliser un tissu d'un passage corporel ou adjacent à un passage corporel
EP2797534A1 (fr) 2011-12-28 2014-11-05 Boston Scientific Scimed, Inc. Dispositif et procédés pour la modulation nerveuse à l'aide d'un nouveau cathéter d'ablation doté d'éléments ablatifs polymères
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US10660703B2 (en) 2012-05-08 2020-05-26 Boston Scientific Scimed, Inc. Renal nerve modulation devices
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
EP3711771A1 (fr) 2012-08-01 2020-09-23 Ikaika Therapeutics, LLC Atténuation de lésions tissulaires et de la fibrose par l'intermédiaire de la protéine de liaison bêta (ltbp4) d'un facteur de croissance de transformation latente
US10321946B2 (en) 2012-08-24 2019-06-18 Boston Scientific Scimed, Inc. Renal nerve modulation devices with weeping RF ablation balloons
EP2895095A2 (fr) 2012-09-17 2015-07-22 Boston Scientific Scimed, Inc. Système et procédé d'électrode à positionnement automatique pour une modulation de nerf rénal
WO2014047411A1 (fr) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. Système de modulation des nerfs et blocage des nerfs par gradient thermique inoffensif
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
WO2014059165A2 (fr) 2012-10-10 2014-04-17 Boston Scientific Scimed, Inc. Dispositifs et procédés de modulation de nerf rénal
CN104936605A (zh) 2012-11-02 2015-09-23 细胞基因公司 激活素-actrii拮抗剂和用于治疗骨和其它病症的用途
WO2014143571A1 (fr) 2013-03-11 2014-09-18 Boston Scientific Scimed, Inc. Dispositifs médicaux pour moduler des nerfs
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
CN105473090B (zh) 2013-03-15 2019-05-03 波士顿科学国际有限公司 重建身体通道的组织或邻近身体通道的组织的方法及装置
JP6139772B2 (ja) 2013-03-15 2017-05-31 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 電極パッドと共に使用するための制御ユニットおよび漏電を推定するための方法
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
JP2016523147A (ja) 2013-06-21 2016-08-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 同乗型電極支持体を備えた腎除神経バルーンカテーテル
CN105473092B (zh) 2013-06-21 2019-05-17 波士顿科学国际有限公司 具有可旋转轴的用于肾神经消融的医疗器械
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
AU2014284558B2 (en) 2013-07-01 2017-08-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
CN105377170A (zh) 2013-07-11 2016-03-02 波士顿科学国际有限公司 具有可伸展电极组件的医疗装置
EP3049007B1 (fr) 2013-07-19 2019-06-12 Boston Scientific Scimed, Inc. Ballonnet de dénervation rénale à électrode bipolaire en spirale
CN105392435B (zh) 2013-07-22 2018-11-09 波士顿科学国际有限公司 具有扭绞球囊的肾神经消融导管
WO2015013205A1 (fr) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Dispositifs médicaux pour l'ablation de nerfs rénaux
WO2015027096A1 (fr) 2013-08-22 2015-02-26 Boston Scientific Scimed, Inc. Circuit flexible ayant une adhérence améliorée à un ballon de modulation de nerf rénal
EP3041425B1 (fr) 2013-09-04 2022-04-13 Boston Scientific Scimed, Inc. Cathéter à ballonnet à radiofréquences (rf) ayant une capacité de rinçage et de refroidissement
CN105530885B (zh) 2013-09-13 2020-09-22 波士顿科学国际有限公司 具有气相沉积覆盖层的消融球囊
CN105592778B (zh) 2013-10-14 2019-07-23 波士顿科学医学有限公司 高分辨率心脏标测电极阵列导管
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
AU2014334574B2 (en) 2013-10-15 2017-07-06 Boston Scientific Scimed, Inc. Medical device balloon
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
US10945786B2 (en) 2013-10-18 2021-03-16 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires and related methods of use and manufacture
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
EP3091922B1 (fr) 2014-01-06 2018-10-17 Boston Scientific Scimed, Inc. Ensemble circuit souple résistant aux déchirures
WO2015119890A1 (fr) 2014-02-04 2015-08-13 Boston Scientific Scimed, Inc. Variante de placement de capteurs thermiques sur une électrode bipolaire
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
BR112016028520A2 (pt) 2014-06-04 2017-10-24 Acceleron Pharma Inc métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
WO2015192111A1 (fr) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Méthodes et compositions de traitement d'ulcères
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
KR102556991B1 (ko) 2014-12-03 2023-07-19 셀진 코포레이션 액티빈-ActRII 길항제 및 빈혈 치료를 위한 용도
WO2016120647A2 (fr) 2015-01-30 2016-08-04 Debreceni Egyetem Régénération musculaire
JP2018510637A (ja) * 2015-03-26 2018-04-19 アクセルロン ファーマ， インコーポレイテッド フォリスタチン関連融合タンパク質およびその使用
HU230620B1 (hu) 2015-05-14 2017-04-28 ALU-ÖNTŐ Fémöntő és Fémmegmunkáló Ipari Eljárás vékonyfalú, tagolt, részletgazdag alumínium öntvények homokformázásos technológiával, gravitációs öntéssel történő előállítására
JP2019509735A (ja) * 2016-03-04 2019-04-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド デュシェンヌ型筋ジストロフィー治療における組換えフォリスタチン−Ｆｃ融合タンパク質及び使用
ES2969882T3 (es) 2018-03-19 2024-05-23 Regeneron Pharma Ensayos y reactivos de electroforesis capilar en microchip
US20220143136A1 (en) 2018-12-21 2022-05-12 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US181033A (en) * 1876-08-15 Improvement in fire-kindlers
US150577A (en) * 1874-05-05 Improvement in grain-separators
US43232A (en) * 1864-06-21 Improvement in preserving fruits
US162714A (en) * 1875-04-27 Improvement in balanced and cut-off valves
US223966A (en) * 1880-01-27 Vapor-burner
US77053A (en) * 1868-04-21 Improvement in mitre-gauges
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP2272959A1 (fr) 1993-05-12 2011-01-12 Genetics Institute, LLC Compositions contenant la BMP-11
KR100328752B1 (ko) 1993-08-26 2002-09-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 인간골형태발생단백질을사용한신경재생법
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
WO1996001845A1 (fr) 1994-07-08 1996-01-25 The Johns Hopkins University School Of Medicine Facteur 11 de differentiation de croissance
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1998033887A1 (fr) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Facteur-8 de differenciation de croissance
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO1999010364A1 (fr) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatine-3
AU1276399A (en) 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
US5942420A (en) 1997-11-17 1999-08-24 Millennium Biotherapeutics, Inc. Molecules of the follistatin-related protein family and uses therefor
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
ES2330062T3 (es) 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
EP1105477A1 (fr) 1998-08-20 2001-06-13 Regeneron Pharmaceuticals, Inc. Dcr5, proteine de fixation de proteines morphogenetiques osseuses, et ses applications
MXPA01007366A (es) 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
WO2001064888A2 (fr) * 2000-02-29 2001-09-07 Zymogenetics, Inc. Polypeptide zkun8 a domaine kunitz
US20020004224A1 (en) * 2000-02-29 2002-01-10 Sheppard Paul O. Kunitz domain polypeptide zkun8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL374966A1 (en) * 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
KR20040094709A (ko) 2002-02-21 2004-11-10 와이어쓰 폴리스타틴 도메인을 포함하는 단백질
AU2003267246A1 (en) 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP2272864A3 (fr) 2002-12-20 2011-02-16 Amgen Inc. Agents de liaison qui inhibent la myostatine

Also Published As

Publication number Publication date
JP2005534616A (ja) 2005-11-17
JP2010031018A (ja) 2010-02-12
MXPA04008150A (es) 2005-06-17
PL375045A1 (en) 2005-11-14
US7585835B2 (en) 2009-09-08
US20070134258A1 (en) 2007-06-14
KR20040094709A (ko) 2004-11-10
NO20043886L (no) 2004-09-16
WO2003072715A3 (fr) 2006-11-02
JP4429729B2 (ja) 2010-03-10
US20030162714A1 (en) 2003-08-28
AU2003217612A1 (en) 2003-09-09
WO2003072715A2 (fr) 2003-09-04
WO2003072715A8 (fr) 2005-01-13
US7956038B2 (en) 2011-06-07
US7541154B2 (en) 2009-06-02
EP1572909A4 (fr) 2007-06-06
US20100021462A1 (en) 2010-01-28
BR0307907A2 (pt) 2011-07-05
US7192717B2 (en) 2007-03-20
CA2476887A1 (fr) 2003-09-04
EP1572909A2 (fr) 2005-09-14
US20050106154A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
IL163525A0 (en) A follistatin domain containing protein
EP1572934A4 (fr) Domaine follistatine contenant des proteines
GB0226251D0 (en) Acetylated protein
AU2003205623A8 (en) Prion protein carrier-conjugates
ZA200406449B (en) Follistatin domain containing proteins
GB0208089D0 (en) Protein
GB0201808D0 (en) Protein
PL376318A1 (en) Protein modification
AU2003278718A8 (en) Stars-a muscle-specification-binding protein
AU2003254669A8 (en) Protein containing a burp domain
GB0220038D0 (en) Novel Protein Design
GB0202748D0 (en) Protein
GB0204735D0 (en) Protein
GB0216601D0 (en) Modified protein
GB0207141D0 (en) Modified protein
GB0203159D0 (en) Protein
GB0204739D0 (en) Protein
GB0203157D0 (en) Protein
GB0203158D0 (en) Protein
GB0202666D0 (en) Protein
GB0203155D0 (en) Protein
GB0204476D0 (en) Protein
GB0203160D0 (en) Protein
GB0203040D0 (en) Protein
GB0202668D0 (en) Protein